Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 7/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.32 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863594 | 1.00 | KCNN3 (0.38) | KCNN3PIK3CDMAPKAPK2IDH1PIK3R1 | |
| SCHEMBL864162 | 0.88 | PIK3CD (0.38) | KCNN3PIK3CDPIK3R1KDM4EKCNN1 | |
| SCHEMBL864163 | 0.88 | PIK3CD (0.38) | KCNN3PIK3CDPIK3R1KDM4EKCNN1 | |
| SCHEMBL863650 | 0.84 | IRAK1 (0.39) | KCNN3PIK3CDIDH1PIK3R1 | |
| SCHEMBL863649 | 0.84 | IRAK1 (0.39) | KCNN3PIK3CDIDH1PIK3R1 | |
| SCHEMBL864188 | 0.79 | MAPK1 (0.43) | — | |
| SCHEMBL864189 | 0.79 | MAPK1 (0.43) | — | |
| SCHEMBL2115716 | 0.77 | PIK3CD (0.35) | KCNN3PIK3CDPIK3R1KDM4E | |
| SCHEMBL863343 | 0.77 | KDM4E (0.44) | PIK3CDKDM4E | |
| SCHEMBL863344 | 0.77 | KDM4E (0.44) | PIK3CDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | KCNN3 1241/4885PIK3CD 14/4885MAPKAPK2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.